CRBP
Corbus Pharmaceuticals Holding
6.10$
-3.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -49.4% | +244.4% | -72.9% | +127.4% | -406.4% | – | -10.2% | +27.8% | +76.7% | -2.2% | +1,442.9% | -91.1% | -0.6% | -31.5% | -83.7% | +329.8% | -46.5% | -1.6% | -78.9% | -28.7% | -1,006.0% | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +24.7% | +18.3% | -9.5% | -2.4% | -56.6% | +300.2% | +5.1% | +24.8% | +23.2% | +38.0% | +1.8% | -0.1% | +6.0% | +2.0% | +28.1% | -10.3% | -41.5% | -33.5% | +5.1% | -26.2% | -95.5% | -1.8% | +0.5% | +1.2% | -0.2% | -2.8% | -56.5% | -3.5% | -3.2% | +2.5% | +31.8% | +0.0% | -27.0% | +10,613.7% | -99.4% | – | – | +0.0% | +2.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -383.0% | – | – | – | -9,282.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +24.7% | +18.3% | -9.5% | -2.4% | +47.4% | +17.8% | +5.1% | +24.8% | +23.2% | +38.0% | +1.8% | -0.1% | +6.0% | +2.0% | +28.1% | -10.3% | -41.5% | -33.5% | +5.1% | -22.8% | -33.7% | -43.0% | -23.9% | +64.4% | +52.0% | +114.5% | -68.3% | +54.2% | +6.6% | -17.5% | +19.1% | +57.4% | -18.7% | +78.0% | -2.9% | +37.4% | -11.8% | +7.7% | +57.3% | – | |
| – | +45.8% | -7.3% | -21.1% | +13.4% | +20.9% | +18.4% | -2.0% | +6.5% | +17.5% | +77.3% | -21.4% | +6.3% | +28.1% | +8.6% | +0.5% | -0.7% | -30.2% | -0.4% | +4.3% | -9.4% | -16.2% | +23.5% | -7.5% | -15.8% | +11.8% | -14.2% | +0.8% | -25.5% | +6.3% | +23.6% | +6.8% | +13.9% | -18.7% | +8.3% | -4.1% | -10.3% | +0.1% | +26.0% | +11.8% | – | |
| – | +30.8% | +10.0% | -12.6% | +1.5% | +40.1% | +18.0% | +3.4% | +20.7% | +22.1% | +45.5% | -3.6% | +1.1% | -77.3% | +22.7% | +399.1% | -80.0% | -30.2% | -0.4% | +4.3% | +1.5% | +70.1% | -15.3% | -14.5% | +12.0% | +38.3% | +60.2% | -52.7% | +15.9% | +4.9% | -3.3% | +12.1% | +43.7% | -19.6% | -66.8% | +361.0% | +28.2% | -10.0% | +10.4% | +49.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -1,571.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +271.5% | -78.8% | +285.9% | +723.4% | +321.9% | +11.1% | +30.9% | +0.8% | -8.8% | +36.7% | +34.1% | -34.7% | – | – | -87.6% | +3,491.7% | +226.4% | -56.4% | -38.0% | -2.3% | -0.2% | +17.4% | +6.8% | +10.5% | +18.3% | +5.8% | +48.7% | -24.3% | -7.4% | -75.0% | +268.3% | -41.6% | +73.7% | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -1,065.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -116.6% | – | -58.7% | +65.5% | -2,009.6% | – | – | – | – | – | – | – | – | – | – | – | -30.6% | 0.0% | -67.0% | +59.2% | +527.0% | -21.3% | +604.9% | -98.3% | -66.2% | +1,333.5% | -17.6% | +6.5% | -100.0% | +100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -1,065.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -1,337.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.